BioDrugs

, Volume 13, Issue 6, pp 381–390 | Cite as

Delivery of Immunoprophylactics in Transgenic Plants

Current Status
Leading Article

Abstract

The search for economic alternatives for the production of recombinant immunoprophylactics has resulted in the concept of generating them in plants at relatively low cost. Two basic strategies are employed: the expression of recombinant antigens or antibodies in transgenic plants, or the presentation of small antigen epitopes on the surface of genetically modified plant viruses. Both approaches have resulted in the production of biologically active immunoprophylactics that have been shown in animal studies to protect from the development of disease symptoms. An especially interesting feature of producing vaccines in edible plant parts is the potential to use the transgenic plant as a vehicle for oral delivery. Substantial progress has been made over the past few years, and the first clinical trials have demonstrated the potential of this new technology. Future challenges are to express the immunoprophylactics at controlled, high concentrations in plants that could be grown locally where they are needed, and to develop easy and standardised administration procedures.

Keywords

Transgenic Plant Tobacco Mosaic Virus Transgenic Potato Cowpea Mosaic Virus Mink Enteritis Virus 

Notes

Acknowledgements

Financial support from Fundação de Amparo à Pesquisa do Estado de Rio de Janeiro (FAPERJ) and from Fundação Estadual do Norte Fluminense (FENORTE) is gratefully acknowledged.

References

  1. 1.
    Fox JL. WHO and UNICEF find vaccines too costly. Nat Biotechnol 1996; 14: 1532Google Scholar
  2. 2.
    Hausdorff WP. Prospects for the use of new vaccines in developing countries: cost is not the only impediment. Vaccine 1996; 14: 1179–86PubMedCrossRefGoogle Scholar
  3. 3.
    Ruedl C, Wolf H. Features of oral immunization. Int Arch Allergy Immunol 1995; 108: 334–9PubMedCrossRefGoogle Scholar
  4. 4.
    McElroy D. The industrialization of plant transformation. Nat Biotechnol 1996; 14: 715–6PubMedCrossRefGoogle Scholar
  5. 5.
    Mason HS, Arntzen CJ. Transgenic plants as vaccine production systems. Trends Biotechnol 1995; 13: 388–92PubMedCrossRefGoogle Scholar
  6. 6.
    Hansen E. Production of recombinant antigens in plants for animal and human immunization: a review. Braz J Genet 1997; 20: 703–11CrossRefGoogle Scholar
  7. 7.
    Richter L, Kipp PB. Transgenic plants as edible vaccines. In: Hammons J, McGarvey P, Yusibov V, editors. Plant biotechnology: new products and applications. Berlin: Springer-Verlag, 1999: 159–76. (Curr Top Microbiol Immunol; 240)Google Scholar
  8. 8.
    Tacket CO, Mason HS, Losonsky G, et al. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat Med 1998; 4: 607–9PubMedCrossRefGoogle Scholar
  9. 9.
    Mason HS, Lam DMK, Arntzen J. Expression of hepatitis B surface antigen in transgenic plants. Proc Natl Acad Sci U S A 1992; 89: 11745–9PubMedCrossRefGoogle Scholar
  10. 10.
    Thanavala Y, Yang YF, Lyons P, et al. Immunogenicity of transgenic plant-derived hepatitis B surface antigen. Proc Natl Acad Sci U S A 1995; 92: 3358–61PubMedCrossRefGoogle Scholar
  11. 11.
    Arakawa T, Chong DKX, Langridge WH0R. Efficacy of a food plant-based oral toxin B subunit vaccine. Nat Biotechnol 1998; 16: 292–7PubMedCrossRefGoogle Scholar
  12. 12.
    Mason HS, Haq TA, Clements JD, et al. Edible vaccine protects mice against Escherichia coli heat-labile enterotoxin (LT): potatoes expressing a synthetic LT-B gene. Vaccine 1998; 16: 1336–43PubMedCrossRefGoogle Scholar
  13. 13.
    Kapusta J, Modelska A, Figlerowicz M, et al. A plant-derived edible vaccine against hepatitis B virus. FASEB J 1999; 13: 1796–9PubMedGoogle Scholar
  14. 14.
    Hiatt AC, Cafferkey R, Bowdish K. Production of antibodies in transgenic plants. Nature 1989; 342: 76–8PubMedCrossRefGoogle Scholar
  15. 15.
    During K, Hippe S, Kreuzaler F, et al. Synthesis and selfassembly of a functional monoclonal antibody in transgenic Nicotiana tabacum. Plant Mol Biol 1990; 15: 281–93PubMedCrossRefGoogle Scholar
  16. 16.
    Hiatt AC. Antibodies produced in plants. Nature 1990; 344: 469–70PubMedCrossRefGoogle Scholar
  17. 17.
    Ma JK, Hikmat BY, Wycoff K, et al. Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in human. Nat Med 1998; 4: 601–6PubMedCrossRefGoogle Scholar
  18. 18.
    Zeitlin L, Olmsted SS, Moench TR, et al. A humanized monoclonal antibody produced in transgenic plants for immuno-protection of the vagina against genital herpes. Nat Biotechnol 1998; 16: 1361–4PubMedCrossRefGoogle Scholar
  19. 19.
    Russell DA. Feasibility of antibody production in plants for human therapeutic use. In: Hammons J, McGarvey P, Yusibov V, editors. Plant biotechnology: new products and applications. B rlin: Springer-Verlag, 1999: 119–38. (Curr Top Microbiol Immunol; 240)Google Scholar
  20. 20.
    Cabanes-Macheteau M, Fitchette-Laine AC, Loutelier-Bourhis C, et al. N-Glycosylation of a mouse IgG expressed in transgenic tobacco plants. Glycobiology 1999; 9: 365–72PubMedCrossRefGoogle Scholar
  21. 21.
    Sun JB, Rask C, Olsson T, et al. Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. Proc Natl Acad Sci U S A 1996; 93: 7196–201PubMedCrossRefGoogle Scholar
  22. 22.
    Bergerot I, Ploix C, Petersen J, et al. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc Natl Acad Sci U S A 1997; 94: 4610–4PubMedCrossRefGoogle Scholar
  23. 23.
    Arakawa T, Yu J, Chong DKX, et al. Aplant-based cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes. Nat Biotechnol 1998; 16: 934–8PubMedCrossRefGoogle Scholar
  24. 24.
    Arakawa T, Chong DKX, Yu J, et al. Suppression of autoimmune diabetes by a plant-delivered cholera toxin B subunit-human glutamate decarboxylase fusion protein. Transgenics 1999; 3: 51–60Google Scholar
  25. 25.
    McGarvey PB, Hammond J, Dienelt MM, et al. Expression of the rabies virus glycoprotein in transgenic tomatoes. Biotechnology 1995; 13: 1484–7PubMedCrossRefGoogle Scholar
  26. 26.
    Haq TA, Mason HS, Clements JD, et al. Oral immunization with a recombinant bacterial antigen produced in transgenic plants. Science 1995; 268: 714–6PubMedCrossRefGoogle Scholar
  27. 27.
    Hein MB, Yeo TC, Wang F, et al. Expression of cholera toxin subunits in plants. Ann N Y Acad Sci 1996; 792: 50–6PubMedCrossRefGoogle Scholar
  28. 28.
    Mason HS, Ball M, Shi X, et al. Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc Natl Acad Sci U S A 1996; 93: 5335–40PubMedCrossRefGoogle Scholar
  29. 29.
    Carrillo C, Wigdorovitz A, Oliveros JC, et al. Protective immune response to foot-and-mouth disease virus with VP1 expressed in transgenic plants. J Virol 1998; 72: 1688–90PubMedGoogle Scholar
  30. 30.
    Wigdorovitz A, Carrillo C, Santos MJD, et al. Induction of a protective antibody response to foot and mouth disease virus in mice following oral or parenteral immunization with alfalfa transgenic plants expressing the viral structural protein VP1. Virology 1999; 255: 347–53PubMedCrossRefGoogle Scholar
  31. 31.
    Sandhu JS, Osadjan MD, Krasnyanski SF, et al. Enhanced expression of the human respiratory syncytial virus-F gene in apple leaf protoplasts. Plant Cell Rep 1999; 18: 394–7CrossRefGoogle Scholar
  32. 32.
    Castañón S, Marín MS, Martín-Alonso JM, et al. Immunization with potato plants expressing VP60 protein protects against rabbit hemorrhagic disease virus. J Virol 1999; 73: 4452–5PubMedGoogle Scholar
  33. 33.
    Usha R, Rohll JB, Spall VE, et al. Expression of an animal virus antigenic site on the surface of a plant virus particle. Virology 1993; 197: 366–74PubMedCrossRefGoogle Scholar
  34. 34.
    Porta C, Spall VE, Loveland J, et al. Development of cowpea mosaic virus as a high-yielding system for the presentation of foreign peptides. Virology 1994; 202: 949–55PubMedCrossRefGoogle Scholar
  35. 35.
    McLain L, Dimmock NJ. Single- and multi-hit kinetics of IgG-neutralization of human immunodeficiency virus type 1 by monoclonal antibodies. J Gen Virol 1994; 75: 1457–60PubMedCrossRefGoogle Scholar
  36. 36.
    McLain L, Porta C, Lomonossoff GP, et al. Human immunodeficiency virus type-1 neutralizing antibodies raised to a glycoprotein 41 peptide expressed on the surface of a plant virus. AIDS Res Hum Retroviruses 1995; 11: 327–34PubMedCrossRefGoogle Scholar
  37. 37.
    McLain L, Durrani Z, Wisniewski LA, et al. Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22 amino acid peptide of gp41 expressed on the surface of a plant virus. Vaccine 1996; 14: 799–810PubMedCrossRefGoogle Scholar
  38. 38.
    Dalsgaard K, Uttenthal Å, Jones TD, et al. Plant-derived vaccine protects target animals against a viral disease. Nat Bio-technol 1997; 15: 248–52CrossRefGoogle Scholar
  39. 39.
    Fitchen J, Beachy RN, Hein MB. Plant virus expressing hybrid coat protein with added murine epitope elicits autoantibody response. Vaccine 1995; 13: 1051–7PubMedCrossRefGoogle Scholar
  40. 40.
    Turpen TH, Reinl SJ, Charoenvit Y, et al. Malarial epitopes expressed on the surface of recombinant tobacco mosaic virus. Biotechnology 1995; 13: 53–7PubMedCrossRefGoogle Scholar
  41. 41.
    Yusibov V, Modelska A, Steplewski K, et al. Antigens produced in plants by infection with chimeric plant viruses immunize against rabies virus and HIV-1. Proc Natl Acad Sci U S A 1997; 94: 5784–8PubMedCrossRefGoogle Scholar
  42. 42.
    McInerney TL, Brennan FR, Jones TD, et al. Analysis of the ability of five adjuvants to enhance immune responses to a chimeric plant virus displaying an HIV-1 peptide. Vaccine 1999; 17: 1359–68PubMedCrossRefGoogle Scholar
  43. 43.
    Modelska A, Dietzschold B, Sleysh N, et al. Immunization against rabies with plant-derived antigen. Proc Natl Acad Sci U S A 1998; 95: 2481–5PubMedCrossRefGoogle Scholar
  44. 44.
    Fernández-Fernández MR, Mart ínez-Torrecuadrada, Casal JI, et al. Development of an antigen presentation system based on plum pox potyvirus. FEBS Lett 1998; 427: 229–35PubMedCrossRefGoogle Scholar
  45. 45.
    Koo M, Bendahmane M, Lettieri GA, et al. Protective immunity against murine hepatitis virus (MHV) induced by intranasal or subcutaneous administration of hybrids of tobacco mosaic virus that carries an MHV epitope. Proc Natl Acad Sci U S A 1999; 96: 7774–9PubMedCrossRefGoogle Scholar
  46. 46.
    McCormick AA, Kumagai MH, Hanley K, et al. Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants. Proc Natl Acad Sci U S A 1999; 96: 703–8PubMedCrossRefGoogle Scholar
  47. 47.
    Brennan FR, Jones TD, Gilleland LB, et al. Pseudomonas aeruginosa outer-membrane protein F epitopes are highly immunogenic in mice when expressed on a plant virus. Microbiology 1999; 145: 211–20PubMedCrossRefGoogle Scholar
  48. 48.
    Brennan FR, Gilleland LB, Staczek J, et al. A chimaeric plant virus vaccine protects mice against a bacterial infection. Microbiology 1999; 145: 2061–7PubMedCrossRefGoogle Scholar
  49. 49.
    Brennan F, Bellaby T, Helliwell S, et al. Chimeric plant virus particles administered nasally or orally induce systemic and mucosal immune responses in mice. J Virol 1999; 73: 930–8PubMedGoogle Scholar
  50. 50.
    Brennan FR, Jones TD, Longstaff M, et al. Immunogenicity of peptides derived from a fibronectin-binding protein of 5. aureus expressed on to different plant viruses. Vaccine 1999; 17: 1846–57PubMedCrossRefGoogle Scholar
  51. 51.
    Verch T, Yusibov V, Koprowski H. Expression and assembly of a full-length monoclonal antibody in plants using a plant virus vector. J Immunol Methods 1998; 220: 69–75PubMedCrossRefGoogle Scholar
  52. 52.
    Mariani C, De Beuckeleer M, Truettner J, et al. Induction of male sterility in plants by a chimaeric ribonuclease gene. Nature 1990; 347: 737–41CrossRefGoogle Scholar
  53. 53.
    Mariani C, Gossele V, De Beuckeleer M, et al. A chimaeric ribonuclease-inhibitor gene restores fertility to male sterile plants. Nature 1992; 357: 384–7CrossRefGoogle Scholar
  54. 54.
    Traavik T. Too early may be too late: ecological risks associated with the use of naked DNA as a biological tool for research, production and therapy. Research Report for the Directorate for Nature Management. Trondheim: Norway, 1999Google Scholar
  55. 55.
    Nielsen KM, Bones AM, Smalla K, et al. Horizontal gene transfer from transgenic plants to terrestrial bacteria: a rare event? FEMS Microbiol Rev 1998; 22: 79–103PubMedGoogle Scholar
  56. 56.
    Leite A, Kemper EL, Silva MJ, et al. Expression of correctly processed human growth hormone in seeds of transgenic tobacco plants. Mol Breed 1999; 9: 1–7Google Scholar
  57. 57.
    Kusnadi AR, Hood EE, Witcher DR, et al. Production and purification of two recombinant proteins from transgenic corn. Biotechnol Prog 1998; 14: 149–55PubMedCrossRefGoogle Scholar
  58. 58.
    Hood EE, Kusnadi AR, Nikolov ZL, et al. Molecular farming of industrial proteins from transgenic maize. In: Shahidi F, Kolodziejcyk P, Whitaker J, et al., editors. Chemicals via higher plant engineering. New York (NY): Plenum Publishing Corp., 1999: 127–48CrossRefGoogle Scholar
  59. 59.
    Miele L. Plants as bioreactors for biopharmaceuticals: regulatory considerations. Trends Biotechnol 1997; 15: 45–50PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  1. 1.Laboratório de Biotecnologia, Centro de Biociências e BiotecnologiaUniversidade Estadual do Norte FluminenseCampos dos Goytacazes, Rio de JaneiroBrazil

Personalised recommendations